Related Experiment Video

Updated: Jun 16, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

[New antiarrhythmic drugs for atrial fibrillation]

M-D Drici1

  • 1Service de Pharmacologie-Toxicologie, Hôpital Pasteur, 30, Avenue de Voie Romaine, 06002 Nice cedex 01, France. drici.md@chu-nice.fr

Annales De Cardiologie Et D'Angeiologie
|January 28, 2010
PubMed

Insights

New antiarrhythmic drugs target atrial fibrillation, a common condition linked to stroke. Current drugs targeting sodium (Na) and potassium (K) channels can be proarrhythmic, necessitating novel approaches.

Area of Science:

  • Cardiovascular pharmacology
  • Cardiac electrophysiology

Context:

  • Atrial fibrillation (AF) is prevalent and a major cause of cerebrovascular thrombosis.
  • Traditional antiarrhythmic drugs targeting I(Na) and I(K) channels can be proarrhythmic, negatively impacting patient outcomes.
  • Amiodarone's efficacy in AF has spurred the development of new drugs.

Purpose:

  • To explore the development of novel antiarrhythmic drugs for atrial fibrillation.
  • To address the limitations of traditional antiarrhythmic therapies.
  • To investigate drugs targeting specific atrial currents like I(Kur) and I(KAch).

Summary:

  • New antiarrhythmic drug development focuses on atrial fibrillation due to its prevalence and association with stroke.
  • Drugs targeting specific atrial currents (I(Kur), I(KAch)) are being developed to overcome the proarrhythmic risks of non-selective I(Na) and I(K) blockade.
  • These novel agents often share pharmacodynamic properties with amiodarone, challenging the existing Vaughan-Williams classification.

Impact:

  • Development of safer and more effective antiarrhythmic treatments for atrial fibrillation.
  • Improved patient outcomes by reducing the risk of proarrhythmia and stroke.
  • Potential re-evaluation of antiarrhythmic drug classification systems.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Robotic Ablation of Atrial Fibrillation11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...